Endothelin-1 is a vasoactive peptide that activates both the endothelin A (ET A ) and endothelin B (ET B ) receptors, and is secreted in high concentrations in many different cancer environments. Although ET A receptor activation has an established nociceptive effect in cancer models, the role of ET B receptors on cancer pain is controversial. EDNRB, the gene encoding the ET B receptor, has been shown to be hypermethylated and transcriptionally silenced in many different cancers. In this study we demonstrate that EDNRB is heavily methylated in human oral squamous cell carcinoma lesions, which are painful, but not methylated in human oral dysplasia lesions, which are typically not painful. ET B mRNA expression is reduced in the human oral squamous cell carcinoma lesions as a consequence of EDNRB hypermethylation. Using a mouse cancer pain model, we show that ET B receptor re-expression attenuates cancer-induced pain. These findings identify EDNRB methylation as a novel regulatory mechanism in cancer-induced pain and suggest that demethylation therapy targeted at the cancer microenvironment has the potential to thwart pain-producing mechanisms at the source, thus freeing patients of systemic analgesic toxicity. Ó
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Introduction
For almost all oral cancer patients, pain is rated as the worst symptom over all other symptoms. Oral cancer patients suffer severe pain for months and even years, preventing them from functioning normally [5, 6, 11, 12, 19] . The intensity of oral cancer pain is higher than that of other cancers [23, 24] . Oral cancer pain escalates with disease progression, so that terminal patients experience excruciating pain during their final months of life. Most oral cancer patients with severe pain are terminal patients. Approximately 50% of oral cancer patients will not be cured with surgery, chemotherapy, or radiation therapy [36] . In the United States this group, which consists of approximately 40,000 new cases per year, is larger than those dying of melanoma, cervical cancer, or ovarian cancer [27] .
Cancer pain, including oral cancer pain, is due to the production of nociceptive mediators such as endothelin-1 (ET-1) into the cancer microenvironment [30, 35] . ET-1 is a vasoactive peptide that is produced and secreted into the cancer microenvironment in high concentration by many cancers, including prostate, ovarian, breast, renal, bladder, cervical, bone, and oral [2,4,13,28,30,32-35,37] . Oral squamous cell carcinoma (SCC), in particular, expresses extremely high levels of ET-1 compared with other cancers [29] . ET-1 binds two receptors, the endothelin A (ET A ) and the endothelin B (ET B ) receptors. ET A receptors have an established role in neuropathic and inflammatory pain [1, 7, 14] . Activation of ET A receptors also contributes to cancer pain. We have confirmed that it is the ET A receptors on the primary afferent nerves within the cancer microenvironment that lead to significant pain [30, 32, 35] .
Unlike ET A receptor activation, evidence suggests that ET B receptor activation has an antinociceptive effect in both noncancer and cancer models [17, 28] . Khodorova et al. demonstrated that ET B receptor activation on keratinocytes leads to an analgesic effect. Oral SCC consists of malignant keratinocytes. However, EDNRB, the gene encoding ET B receptors, is frequently methylated in cancer. EDNRB methylation results in transcriptional silencing and has been demonstrated in cancers of many types, including lung, prostate, esophageal, and nasopharyngeal cancer [15, 18, 21, 39] .
In this study, we hypothesize that EDNRB is silenced through promoter methylation in oral SCC and that hypermethylation of this gene contributes to cancer induced pain. To investigate the
